Background With the essential role of interleukin-1 signaling in cancer-related inflammation,
IL-1R1, the main receptor for both IL-1α and IL-1β, demonstrated therapeutic potential in …

Background: Interleukin-1 receptor type II (IL-1R2), also known as CD121b, is a member of
the IL-1 receptor family. IL-1R2 acts as negative regulator of the IL-1 system, modulating IL-1 …

ABSTRACT Interleukin-9 (IL-9) is a T cell cytokine that is associated with inflammation and
allergy, but the expression level of IL-9 in gastric cancer and its clinical significance are less …

Systemic chemotherapy with multiple drug regimens is the main therapy option for advanced
gastric cancer (GC) patients. However, many patients develop relapse soon. Here, we …

Tumors develop numerous strategies to fine-tune inflammation and avoid detection and
eradication by the immune system. The identification of mechanisms leading to local …

Despite advances in diagnostic imaging, surgical techniques, and systemic therapy, gastric
cancer (GC) is the third leading cause of cancer-related death worldwide. Unfortunately …

In recent years, immunotherapy, particularly PD-1 antibodies, have significantly enhanced
the outcome of gastric cancer patients. Despite these advances, some patients do not …

Background There is still a therapeutic challenge in treating gastric cancer (GC) due to its
high incidence and poor prognosis. Collagen type V alpha 2 (COL5A2) is increased in …

Background. Immunotherapy is a promising therapy for metastatic gastric cancer (GC)
patients. However, the component of tumor microenvironment (TME) is a pivotal factor …

Background Although the tumor stroma in solid tumors like gastric cancer (GC) plays a
crucial role in chemo-resistance, specific targets to inhibit the interaction between the …